Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Borderline resectable pancreatic ductal adenocarcinoma
Data

Cancers·Borderline resectable pancreatic ductal adenocarcinoma

DataBorderline resectable pancreatic ductal adenocarcinoma

Back to the Borderline resectable pancreatic ductal adenocarcinoma hub →57 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview What it is Finding it Treating it Evidence The science Where you are Living with it What is coming Data

Data

Related pages

57

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
Pancreatic acinar cell carcinoma
Shares Richard Schulick, PDAC organoid pharmacotyping, Whipple procedure (pancreaticoduodenectomy), Eileen M. O'Reilly and the tags subtype-page, gastrointestinal.
Cancer
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Shares Marc G. Besselink, Richard Schulick, Resectable, borderline resectable and unresectable, PRODIGE 24 / CCTG PA6 and the tags subtype-page, gastrointestinal.
Cancer
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Shares PRODIGE 24 / CCTG PA6, Whipple procedure (pancreaticoduodenectomy), Eileen M. O'Reilly, Gemcitabine + nab-paclitaxel and the tags subtype-page, gastrointestinal.
Cancer
KRAS wild-type pancreatic ductal adenocarcinoma
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Eileen M. O'Reilly, Gemcitabine + nab-paclitaxel, FOLFIRINOX / mFOLFIRINOX and the tags subtype-page, gastrointestinal.
Cancer
Pancreatoblastoma
Shares Resection margins (R0 / R1 / R2), Whipple procedure (pancreaticoduodenectomy), Pancreatic cancer (KEGG map), Resectable pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares Whipple procedure (pancreaticoduodenectomy), CT (computed tomography), KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Localised anal squamous cell carcinoma (stage I to III)
Shares Chemoradiation (chemoradiotherapy, CRT), Robotic & minimally invasive surgery, Capecitabine, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Shares CT (computed tomography), KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.

technologies

13

Biliary stenting and drainage CT (computed tomography)Cytotoxic chemotherapy Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)KRAS & RAS inhibitors Liquid biopsy (ctDNA)MR-guided adaptive radiotherapy PDAC organoid pharmacotyping Personalised neoantigen (mRNA) vaccines Platinum agents Robotic & minimally invasive surgery SBRT / SABR (stereotactic radiotherapy)Topoisomerase-I inhibitors (and ADC payloads)

targets

2

BRCA1 / BRCA2 (HRD)KRAS

drugs

7

Phase 2Personalised mRNA neoantigen vaccine

Autogene cevumeran

ApprovedOral fluoropyrimidine prodrug (antimetabolite)

Capecitabine · Xeloda

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedNucleoside analogue (deoxycytidine)

Gemcitabine · Gemzar / Infugem

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

ApprovedCytotoxic regimen

NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen

companies

6

BioNTech Dutch Pancreatic Cancer Group Eli Lilly (incl. Loxo)Ipsen Revolution Medicines Roche / Genentech

pathways

2

Fibroblast activation, desmoplasia & matrix stiffness Pancreatic cancer (KEGG map)

terms

9

CA 19-9 Chemoradiation (chemoradiotherapy, CRT)Circulating tumour DNA (ctDNA)Locally advanced and locoregional disease Neoadjuvant / adjuvant / perioperative Resectable, borderline resectable and unresectable Resection margins (R0 / R1 / R2)Stereotactic body radiotherapy (SBRT / SABR)Whipple procedure (pancreaticoduodenectomy)

trials

5

ESPAC-5 Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source PREOPANC-1 / PREOPANC-2 PRODIGE 24 / CCTG PA6 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

ideas

2

Grow each trial patient's tumour as organoids to decide which platform arm opens next RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable

people

6

Albert C. Koong Eileen M. O'Reilly Jürgen Weitz Marc G. Besselink Richard Schulick Theodore S. Hong

key papers

5

Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)ESPAC-5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy in borderline resectable pancreatic cancer ESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Add 11 pancreatic cancer subtype pages · diff · file

Wikipedia

Pancreatic cancer

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Machine-readable versions of Borderline resectable pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/borderline-resectable-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id borderline-resectable-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.